908 Devices Inc. (MASS) vs Phathom Pharmaceuticals, Inc. (PHAT)
A side-by-side comparison of 908 Devices Inc. and Phathom Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MASS
908 Devices Inc.
$12.31HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
PHAT
Phathom Pharmaceuticals, Inc.
$6.78HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — MASS vs PHAT
growth of $100 · dividends reinvested · last 6yMASS -73.9% (-20.0%/yr)PHAT -82.4% (-25.1%/yr)MASS compounded faster over this window
MASS PHAT
MASS vs PHAT: by the numbers
- •PHAT is the larger company ($549M vs $505M market cap).
- •Both run net losses; PHAT's is the smaller (-41.34% vs -56.68% net margin).
Metrics side by side
Valuation
| Metric | MASS | PHAT |
|---|---|---|
| P/S ratio | 8.30 | 2.29 |
| P/B ratio | 3.98 | N/A |
| FCF yield | 0.10% | N/A |
Profitability
| Metric | MASS | PHAT |
|---|---|---|
| Gross margin | 49.79% | 82.92% |
| Operating margin | -46.01% | -91.36% |
| Net margin | -56.68% | -41.34% |
| ROE | -27.20% | N/A |
| ROIC | -18.90% | -23.45% |
Growth (annualized)
| Metric | MASS | PHAT |
|---|---|---|
| Revenue CAGR (5Y) | 18.92% | N/A |
| Total return CAGR (5Y) | -17.66% | -26.93% |
Frequently asked
- How have MASS and PHAT total returns compared?
- Over the past 5 years, MASS delivered -17.66% and PHAT delivered -26.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
908 Devices ROEPhathom Pharmaceuticals ROE908 Devices operating marginPhathom Pharmaceuticals operating margin908 Devices revenue growthPhathom Pharmaceuticals revenue growth908 Devices free cash flowPhathom Pharmaceuticals free cash flow
908 Devices & Phathom Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.